Neuberger Berman Group
CAI

Neuberger Berman Group’s Caris Life Sciences CAI Stock Holding History

Neuberger Berman Group’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64M Buy
3,590,963
+377
+0% +$6.75K 0.04% 449
2026
Q1 		$64.2M Sell
3,590,586
-210,336
-6% -$4.6M 0.05% 426
2025
Q4 		$103M Sell
3,800,922
-544,120
-13% -$15.3M 0.08% 307
2025
Q3 		$109M Sell
4,345,042
-1,894,478
-30% -$60.4M 0.08% 317
2025
Q2 		$167M Buy
+6,239,520
New +$168M 0.13% 191

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Neuberger Berman Group's CAI Position: Q2 2026 in Review

Neuberger Berman Group increased its Caris Life Sciences (CAI) stake by 0.01% in Q2 2026, buying an estimated $6.75K and bringing the position to 3,590,963 shares worth $64M. The position accounts for 0.04% of the portfolio, ranked #449.

Neuberger Berman Group first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $167M in Q2 2025. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Neuberger Berman Group held 3,590,963 shares of Caris Life Sciences worth $64M as of Q2 2026.
  • Neuberger Berman Group bought 377 Caris Life Sciences shares in Q2 2026, an estimated $6.75K.
  • Caris Life Sciences made up 0.04% of Neuberger Berman Group's portfolio in Q2 2026, its #449 holding.
  • Neuberger Berman Group first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • Neuberger Berman Group's Caris Life Sciences position peaked at $167M in Q2 2025.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.